RxDoctor Payments Data

Vinay Chitkara, MD

Cardiology · London, OHNPI 1659336337

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (58.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Penumbra, Inc. at 49.4% of the total.

$8,325in general payments, 2019–2025

Across 121 payments — averaging $68.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$4K
  • Abbott$2K
  • Cardiovascular Systems Inc.$750
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$379
  • Boston Scientific$297
  • Novartis$209
  • plus $674 from 10 others

What the payments were for

  • Travel & lodging$4,82758%
  • Food & beverage$3,48342%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,325 in reported general payments places this provider in the 85th percentile of 30 cardiology providers in Ohio.

See all cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$103,232
Medicare patients
610
Services billed
2,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban816$712,201
XareltoRivaroxaban58$63,919
Repatha SureclickEvolocumab35$31,808
EntrestoSacubitril/Valsartan16$13,088
BrilintaTicagrelor19$7,988
Metoprolol Succinate622$7,443
Clonidine21$4,866
Diltiazem 24hr Er (Cd)Diltiazem Hcl128$3,421
Amiodarone Hcl58$3,074
SotalolSotalol Hcl172$2,915
Atorvastatin Calcium261$2,655
Potassium Chloride153$2,626
ClopidogrelClopidogrel Bisulfate252$2,488
Amlodipine Besylate269$2,347
Losartan Potassium189$1,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$712,201816 claims
Johnson & JohnsonXarelto$30$63,91958 claims
NovartisEntresto$209$13,08816 claims
AstraZenecaBrilinta$56$7,98819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 cardiology providers in Ohio.

Other cardiology in London

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →